Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T13:40:24.073Z.
Calculation as of: 2026-10-06T13:40:24.073Z.
Quote observation: 2026-10-06T13:40:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3dded1d9c7c97f6604bba9f83d6a77d690042e17e53b2ba4f54e500de5eb4a7b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Market Cap
$278.05M
Free Cash Flow Yield
N/A
TTM Avg
41.16%
3Y Avg
41.16%
5Y Avg
41.16%
Market Cap
$281.92M
Free Cash Flow Yield
N/A
TTM Avg
1.78%
3Y Avg
1.78%
5Y Avg
1.78%
Market Cap
$281.49M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$271.74M
Free Cash Flow Yield
N/A
TTM Avg
21.58%
3Y Avg
20.83%
5Y Avg
20.83%
Market Cap
$287.58M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.37M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$289.54M
Free Cash Flow Yield
N/A
TTM Avg
2.65%
3Y Avg
2.65%
5Y Avg
2.65%
Market Cap
$290.35M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aurora Cannabis Inc. (ACB) | $278.74M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $278.05M | N/A | 41.16% | 41.16% | 41.16% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | N/A | 1.78% | 1.78% | 1.78% |
| Fate Therapeutics, Inc. (FATE)vs › | $281.49M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $271.74M | N/A | 21.58% | 20.83% | 20.83% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $287.58M | N/A | N/A | N/A | N/A |
| Century Therapeutics, Inc. (IPSC)vs › | $264.37M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $289.54M | N/A | 2.65% | 2.65% | 2.65% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $290.35M | N/A | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $264.62M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
